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INTRODUCTION
Daikenchuto (DKT) is a traditional Japanese herbal medicine which consists of extracted three botanical raw materials, Japanese pepper, processed ginger, and ginseng radix (Kono et al., 2009 ).
Ever since its approval as a prescription drug in 1986 by the Japanese Ministry of Health, Labour and Welfare, DKT has been widely used by gastroenterologists and surgeons for the treatment of various gastrointestinal disorders such as postoperative ileus and obstructive bowel disease (Itoh et al., 2002; Ohya et al., 2003; Kono et al., 2009) new drug. Among these studies, one recent study reported that DKT has a prokinetic effect in healthy volunteers (Manabe et al., 2010) .
Despite widespread use in clinical practice, the pharmacokinetic (PK) knowledge of DKT is limited. Recently, Iwabu et al. (2010) reported that 44 compounds derived from DKT were detected in the plasma and urine after oral administration of DKT by using the liquid chromatography-tandem mass spectrometry (LC-MS/MS). Moreover, Munekage et al. (2011) reported that the plasma concentration profiles of six pharmacologically active constituents of DKT, hydroxy-α-sanshool (HAS), hydroxyl-β-sanshool (HBS), 6-shogaol (6S), 10-shogaol (10S),
ginsenoside Rb 1 (GRB1), and ginsenoside Rg 1 in Japanese healthy volunteers.
In recent years, the population PK approach has been used for the development of various pharmaceuticals (Williams and Ette, 2000) . This approach can identify the measurable factors that cause changes in the dose-concentration relationship and the extent of these changes (FDA Guidance for Industry, Population Pharmacokinetics, 1999) . In this study, we first sought to develop the population PK models for the five constituents of DKT using the plasma concentration data obtained from healthy volunteers participating in the Japanese or US study.
We then determined whether potential inter-ethnic differences in the pharmacokinetics of DKT existed between the study populations.
method as reported by Munekage et al. (2011) . The limits of the quantification were 0.01 ng/mL for HAS, HBS and GRB1, and 0.02 ng/mL for 6S and 10S.
Population Pharmacokinetic Model Building. Population pharmacokinetic analysis was performed using the Phoenix NLME (Ver 1.3, Certara L.P., St. Louis, Missouri USA) by the Laplacian method.
One-or Two-compartment models with or without extra vascular input was examined for exploration of the mean structure of the modeling. The basic PK parameters used in this study were oral clearance of the central compartment (CL1/F), volume of distribution for the central compartment (V1/F), inter-compartmental clearance (CL2/F), volume of distribution for the peripheral compartment(V2/F), and first-order absorption rate constant (Ka). Non-linear absorption coefficient (b) was introduced for GRB1 population PK modeling as a power of dose (see supplement).
The interoccasion variability and the interindividual variability were modeled by lognormal distribution using Eq. 1; where C obs,ijt is the plasma concentration observed in the i th individual, at time t after the drug administration during the j th period. C ijt is the predicted plasma concentration, and Eps ijt is a random variable which is normally distributed with mean 0 and standard deviation σ .
The combined proportional and additive model;
where proportional error component is obtained as the product of Eps ijt and CMixRatio.
Once the basic model was selected, the influences of covariates were evaluated by a stepwise procedure based on the likelihood ratio test using P< 0.05 as entry criterion. The covariate evaluated were the individual's age, body weight, BMI, gender, and participation in the Japanese or US study (inter-study difference) .
The influences of continuous covariates (age, body weight, and BMI) onto the k th parameter were described as a power model as shown in Eq. 4;
BQL (below the quantification limit) values were treated as the left censored data and used in the model fitting procedure via the maximum likelihood method (Beal, 2001 ).
Model validation.
Bootstrap re-sampling method (Ette, 1997) and visual predictive check method (Post et al., 2008) were used to evaluate the accuracy and robustness of our models. A total of 1000 re-sampling was executed for the bootstrap method, and a total of 1000 replicates of the original dataset were simulated for the predictive check method in order to generate the predicted concentration values and the 95% prediction interval.
Results
Demographics and disposition of the study participants are summarized in Table 1. A total 1859 samples from 55 participants were included in the population PK analysis. There were marked differences in subject demographics. Japanese and US adults. Noticeable differences were observed in the mean plasma concentrations of HAS and HBS between the Japanese and US participants.
Final population PK parameters are summarized in Table 3 Population PK model of HAS was best described by a two-compartment model with a bolus input (see model equation in supplement). Interoccasion variability and interindividual variability were estimated for V1/F, CL1/F, and V2/F. The interindividual variation of PK parameters showed a positive correlation. A combined proportional and additive model was selected to describe the residual variability. BMI and age were the covariates affecting V1/F, V2/F and CL1/F. The relative standard error of estimation (RSE%) for the fixed effect parameters stayed within the range from 2.7% to 32.7% and the RSE% of random effect parameters ranged from 7.8% to 45.5% (Table S1 -1 in supplement). Goodness-of-fit plot for the final population PK model showed no remarkable biases (Figure 4 ). The visual predictive check plots indicated that the predictive concentrations displayed a good fit with the observed concentrations ( Figure S1 -1 in supplement). All of the re-sampling successfully converged in the
(within the range of 2.6% to 30.0%), except for the covariance between Ka and CL1/F, which showed greater RSE% due to the mean value nearly zero. (Table S5 -1 in supplement) Residuals of population prediction and the observed value showed log-normal distribution. On the other hand, individual post-hoc estimation and observed value showed no remarkable biases (Figure 8 ).
The visual predictive check plots indicated that the predictive concentrations were well fitted to the observed concentrations ( Figure S5 -1 in supplement). All of the re-sampling successfully converged in the bootstrap evaluation and the estimated parameters from bootstrap were similar to the parameters obtained from final model (Table S5 -1 in supplement). 
Discussion
We analyzed six pharmacologically active constituents of daikenchuto (DKT), hydroxy-α-sanshool (HAS), hydroxyl-β-sanshool (HBS), 6-shogaol (6S), 10-shogaol (10S), ginsenoside Rb 1 (GRB1), and ginsenoside Rg 1 (GRG1) in respective Japanese and US PK studies.
Population PK models were constructed for the five constituents, but not for GRG1 because most of the GRG1 concentrations fell below detection limit.
When the first-order absorption model and the bolus input model were evaluated as population PK models for HAS, HBS, 6S, and 10S, the bolus input model was found to best describe the PK of these constituents. This was because the t max was observed in many subjects at the first sampling point, which occurred at an early time point of 15 minutes. Wade et al. (1993) reported that when no data are present in the absorption phase, then the misspecification of the rate of drug absorption and/or the model used to describe drug absorption has little consequence on the estimation of the remaining population parameters. On the other hand, the goodness-of-fit plot of the model for 10S indicated that the predicted plasma concentrations overestimated the observed plasma concentrations at the highest predicted plasma concentration, i.e., the first sampling point.
This was based on participants who were actually observed during the absorption phase. Without incorporating the absorption phase into the model, the plasma level in the proximity of C max was unpredictable. Although the modeling is limited to an elimination phase, the model is considered still applicable to the pharmacokinetic characterization of the compound with a short absorption phase.
As reported previously in Japanese PK study (Munekage et al. 2011) , nonlinearity was observed
in AUC of GRB1 but dose-dependence in half-life was not; therefore, non-linear absorption model was assumed for the GRB1 analysis. As the result, nonlinear parameter (b) showed a significant value, and AIC value indicated better fit as compared to the model not assuming the nonlinear parameter. Estimated b value below 1 suggested the convex dose-concentration relationship.
The BQL data included in the dataset were used for the analysis. Although useful information is included in the BQL data, there are concerns regarding the possible bias caused by the mishandling of BQL data. (Hing et al., 2001 , Byon et al., 2008 . Beal (2001) reported an overview of ways to fit a PK model in the presence of BQL data. The method applied conditional likelihood estimation to the observations above BQL and the likelihood for the data being above BQL were maximized with respect to the model parameters. Phoenix NLME, which was the analysis software used in this study, implemented this method. We therefore treated BQL data as left censored data and used them in the model fitting procedure via the maximum likelihood method.
by more detailed examination including the clinical study about efficacy and safety.
Remarkable differences were observed in mean plasma concentrations of HAS and HBS between the Japanese and US participants (Figure 2 and 3) . However, inter-study difference has not been selected for the final models of all constituents of DKT. On the other hand, the simulated plasma concentrations at the median value of covariates in each study could reproduce the study difference observed. These results suggest that the difference in the plasma levels between the study populations could be explained by the difference in terms of demographic factors such as BMI and age, rather than the inter-ethnic difference between the Japanese and the US habitants.
The likelihood ratio test is frequently used as the criteria for the selection of covariates. The possibility of type 1 error inflation in the likelihood ratio test has been cautioned (Wählby et al., 2001 ). Therefore, a very low p value such as p < 0.001 is often used as the significance level.
Nevertheless, as the first exploratory analysis of DKT via population modeling, we set a criterion of p value at 0.05 to increase the probability of detecting a greater number of covariates which might influence pharmacokinetic parameters. In order to protect against the inclusion of false covariates, more evaluations are needed.
sanshools versus those with a long half-life such as ginsenosides. In order to effectively extrapolate our findings to a wider population, further investigation of the relationship between PK and efficacy is warranted.
The results from this study are useful and are a preliminary step towards a more comprehensive PK/PD study in patients. 
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